Sonoma Pharmaceuticals and Microderm Technologies Announce that Dermodacyn® Disinfecting Solution is Now Available in Hong Kong and Thailand
WOODSTOCK, Ga.--(BUSINESS WIRE)-- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, disinfectant use and dermatological conditions, and Microderm Technologies Ltd. announce that Dermodacyn® disinfectant has received import clearance as a medical device for Thailand with the help from Microderm’s partner VetSynova Co. Ltd., Thailand, and is now available online and in pharmacies and stores in Hong Kong and Thailand.
Dermodacyn disinfecting solution is designed to be sprayed as an aerosol to disinfect areas suspected to contain bacteria and viruses that can lead to disease. Dermodacyn disinfectant is medical grade and can be used in hospitals to keep doctors and patients protected and safe. It also performs well in other high traffic areas that require constant cleaning and disinfecting. In a study by the University of Hong Kong and Queen Mary Hospital Dermodacyn disinfecting solution showed it effectively kills the coronavirus SARS-CoV-2. See https://www.journalofhospitalinfection.com/article/S0195-6701(20)30339-X/fulltext.
“We believe the fact that Dermodacyn® can outperform other products to kill viruses and bacteria effectively and at the same time be completely safe to be used on humans will boost customer confidence and help us further expand our customer base into the public service industry,” said Mr. Christopher Lee, Founder and CEO of Microderm Technologies.
“We originally brought Dermodacyn® to customers in Hong Kong and other parts of Asia as a skin antiseptic and wound treatment product before introducing it as a surface disinfectant. This may be the only product to be applied first on humans before being used as a surface disinfectant. This is why Dermodacyn disinfectant is one of the safest and most effective products of its kind in the market. The well-being of our customers is always our priority,” Mr. Lee added.
“Sonoma’s Microcyn technology-based products have been safely and effectively used for over 20 years. We are proud to work with partners like Microderm who are showcasing our technology through consumer channels and highly regarded research institutions,” said Amy Trombly, CEO of Sonoma Pharmaceuticals. “We plan on continuing to research new areas of use and plan to continue to develop new products that will help our customers around the world stay safe and healthy.”
For more information and where to buy Dermodacyn visit https://www.dermodacyn.com/shop.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 54 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Woodstock, Georgia, with manufacturing operations in Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact email@example.com.
About Microderm Technologies Ltd.
Microderm Technologies Ltd. is based out of Hong Kong, and its mission is to improve the quality of lives of people by minimizing the risks of infectious diseases. In collaboration with the inventors of the unique and patented Microcyn® Technology, Microderm launched a revolutionary line of wound healing products, Dermodacyn. This is the first of its kind to be launched in the Hong Kong over-the-counter market for human use. Microderm has made first class wound healing products affordable and easily accessible to every person. At Microderm, we are dedicated to providing safe, effective, and simple solutions to wound treatment that are supported by clinical studies and are internationally recognized.
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “company”). These forward-looking statements are identified by the use of words such as “continue,” “promise,” and “expand,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company’s business that could cause actual results to vary, including such risks resulting from the global COVID-19 pandemic, that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company’s products will not be as large as expected, the company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company’s cash needs, fund further development and clinical studies, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Source: Sonoma Pharmaceuticals, Inc.
Released January 28, 2021